Exelixis (EXEL) Files Patent Infringement Claim Against Teva (TEVA)
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Exelixis (NASDAQ: EXEL) disclosed that on June 17, 2021, the company filed a complaint in the United States District Court for the District of Delaware for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (NASDAQ: TEVA), asserting U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva’s ANDA filing with the FDA. Exelixis is seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA be no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- electroCore (ECOR) Announces Issuance of New Patent for Migraine Treatment using Smartphones
- MyMD Pharmaceuticals (MYMD) Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
- AIkido Pharma (AIKI) Announces Notice of Allowance Issued for Central Nervous System Peptide Technology
Create E-mail Alert Related CategoriesLitigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!